HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.

59 Clinical Trials
Lymphoma Phase I/II Enrolling
nct/study# NCT06542250 / D9960CC00001

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)

Learn More
Lymphoma Phase II Enrolling
nct/study# NCT05389293 / MSK-22-100

An Open-Label, Multicenter, Single-Arm, Phase-2 Study of Single-Agent Mosunetuzumab (BTCT4465A, RO7030816) for the Treatment of Patients with Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy.

Learn More
Lymphoma N/A Enrolling
nct/study# N/A / DCC

Role of Donor Cell Chimerism in Predicting Relapse Post-Transplant in Patients with Hematologic Malignancies

Learn More
Lymphoma N/A Enrolling
nct/study# N/A / MSK20-534

A Multicenter Retrospective Analysis of Outcomes for Rare Subtypes of T-Cell Lymphoma

Learn More
Lymphoma N/A Enrolling
nct/study# N/A / ENGRAFTMENT-SYNDROME

Incidence of Engraftment Syndrome in Classical Hodgkin Lymphoma after Checkpoint Inhibitors: A Retrospective Analysis

Learn More
Lymphoma N/A Enrolling
nct/study# N/A / EZH2

Transcriptional Profiles of CD19 Chimeric Antigen Receptor (CAR) T-cells that Induce Durable Remission in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Learn More

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.